GE Healthcare Medical Diagnostics Relaunches Optison Contrast Agent in Europe

GE Healthcare's (NYSE: GE) Medical Diagnostics division announced the market reintroduction of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in select echocardiograms, in Europe. The product is currently available in Germany, Italy, Spain, Austria, the Nordic countries and the UK with other countries planned to follow in the near future. Optison is indicated for use in patients with suboptimal echocardiograms with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular endocardial border delineation with resulting improvement in wall motion visualisation.1

"We are pleased that Optison is now available to cardiologists, sonography professionals, echocardiography laboratory staff, and most importantly patients,” said Debra Leeves, EMEA Marketing Leader for Medical Diagnostics in GE Healthcare. “The product helps improve the detection of heart disease by converting difficult-to-interpret echocardiograms into clearer visualisations of the heart's left ventricle.”